In a prospective open randomized trial, pefloxacin was given to 53 patients and ceftazidime was given to 50 patients suffering from bronchopneumonia (n = 29), deep soft tissue infection (n = 19), urinary tract infection (n = 28), chronic osteomyelitis in exacerbation (n = 15), chronic otitis media in exacerbation (n = 3), malignant external otitis (n = 3), abdominal abscess (n = 2), septic arthritis (n = 1), acute cholangitis (n = 1), bacterial endocarditis (n = 1), and subacute sinusitis (n = 1). Underlying aggravating factors coexisted in 45 and 41 patients in the pefloxacin and ceftazidime groups, respectively, with 32 and 33 infections characterized as nosocomial and severe in each group, respectively. Pefloxacin was given at a dose of 400 mg intravenously (i.v.) (n = 16) or per os (n = 23) every 8 or 12 h, as well as i.v. followed by per os (n = 14), for 7 to 180 days; and ceftazidime was given at 2 g i.v. every 8 h (n = 45) or 1 g intramuscularly every 8 h (n = 5) for 7 to 56 days. Pseudomonas aeruginosa and various members of the family Enterobacteriaceae predominated in culture specimens. Clinical cure was observed in 38 and 39 patients given pefloxacin and ceftazidime, respectively; 10 and 7 patients were improved; and in 5 and 4 patients treatment failed. Pathogen eradication was observed in 42 and 39 patients, respectively; persistence was observed in 8 and 11 patients, respectively, followed by the emergence of resistance in five and four P. aeruginosa strains, respectively (P = not significant). With the exception of photosensitivity rash in seven patients given pefloxacin, all side effects observed in eight and three patients in the pefloxacin and ceftazidime groups, respectively (P < 0.01), were not important and were self-limited. It is concluded that pefloxacin is as effective as ceftazidime in moderate to severe gramnegative-bacterial infections, with similar trends toward development of resistance during therapy.
Pefloxacin, a new fluorinated piperazinyl-substituted quinolone derivative, has an in vitro spectrum similar to those of the aminoglycosides and broad-spectrum cephalosporins against aerobic gram-negative microorganisms, including strains resistant to the latter antibiotics (16, 29) . It is also active against both methicillin-susceptible and methicillinresistant staphylococci (29) . It is readily absorbed after oral administration but can also be given intravenously. Pefloxacin is characterized by its prolonged elimination half-life (9 to 12 h), and along with ofloxacin it attains higher levels in cerebrospinal fluid than other quinolones and may play an important role in the therapy of gram-negative-bacterial meningitis (9, 17) . Therefore, pefloxacin may be an alternative antibiotic in the treatment of severe systemic infections caused by multiresistant organisms.
Based on pefloxacin in vitro activity and pharmacokinetic properties, a controlled study was designed with patients suffering from a variety of moderate to serious gram-negative-bacterial infections. Ceftazidime was selected as the comparative antibiotic because of its established favorable activity in the therapy of Pseudomonas aeruginosa and enterobacteriaceal infections (4, 6, 10) . Animal model studies in which pefloxacin was compared with aminoglycosides or macrolides have been reported (8, 27) , but to our knowledge a similar comparative study with humans has not been published.
(This study was presented in part previously [H. Giamarellou, N. Galanakis, G. Perdikaris, C. Tsagaraki, and P. Sfikakis, Program Abstr. 27th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 116, 1987] .) * Corresponding author.
MATERIALS AND METHODS
In this controlled study, hospitalized adults and adolescents with a variety of gram-negative-bacterial infections caused by organisms susceptible to both studied antimicrobial agents were included. After informed consent was obtained, ceftazidime and pefloxacin were administered to 54 and 53 patients, respectively, according to an open randomization code. Four patients in the ceftazidime group were dropped from the study because pretherapy cultures were nondiagnostic. Of the remaining 103 patients, 67 were males and 36 were females, and they ranged from 15 to 84 (mean ± standard deviation, 51.5 ± 18.4; median, 52.5) years of age. The sex and age distributions were similar in each group. No significant differences were observed between the groups with respect to renal function, severity or duration of infection, previous therapy for the infection, or the number of hospital-acquired infections.
Of these patients, 15 in the ceftazidime group and 14 in the pefloxacin group had bronchopneumonia, 9 and 10 had deep soft tissue infection, 15 and 13 had urinary tract infection (UTI) (15 and 12 had acute pyelonephritis; there was 1 patient with chronic prostatitis in exacerbation in the pefloxacin group), 7 and 8 had chronic osteomyelitis in exacerbation, 2 and 1 had chronic otitis media in exacerbation, 3 in the pefloxacin group had malignant external otitis, 1 each in the ceftazidime group had septic arthritis and acute cholangitis, and 1 each in the pefloxacin group had bacterial endocarditis, subacute sinusitis, and pancreatic and hepatic abscesses.
The criteria used to diagnose bronchopneumonia, acute pyelonephritis, soft tissue infection, chronic osteomyelitis, malignant external otitis, and chronic prostatitis were iden-PEFLOXACIN VERSUS CEFTAZIDIME 1363 tical to the classical prerequisites previously described by our group (13 (23) . Susceptibilities to ceftazidime and pefloxacin were determined by the Kirby-Bauer method, using 30-and 5-,ug disks, respectively. MICs for the infecting pathogens were determined by the standard tube dilution method in Mueller-Hinton broth (BBL Microbiology Systems) (30) . Bacteria were considered resistant to cephalosporins and amikacin if the MIC was >16 ,ug/ml, to the other aminoglycosides and ampicillin if the MIC was >8 ,ug/ml, to carbenicillin and azlocillin if the MICs were >128 and >64 ,ug/ml, respectively, and to pefloxacin if the MIC was >4 ,ug/ml.
Ceftazidime was supplied in 1-g vials, and pefloxacin was supplied in 400-mg vials and 400-mg tablets. Ceftazidime was administered as an intravenous infusion over a 30-min period at a dose of 2 g every 8 h or intramuscularly at a dose of 1 g every 8 h. Whenever the clinical condition was serious and reliable oral administration was thus not permitted, pefloxacin was given intravenously. Based on the expected higher MICs of pefloxacin against P. aeruginosa and Acinetobacter spp. (16) , whenever these pathogens were implicated pefloxacin was given at a dose of 400 mg every 8 h orally or as an intravenous infusion over a 30-min period followed by orally whenever oral feedings were permitted. In all other gramnegative-bacterial infections, to obtain higher levels during the first 3 critical days of therapy, pefloxacin was given every 8 h for the first 3 days and every 12 h thereafter until the end of therapy. The durations of therapy are shown in Table 1 . Whenever the nature of the underlying infection was suspicious for the coexistence of anaerobes and since transtracheal aspiration was not performed in any patient with bronchopneumonia, metronidazole was added for 11 patients and clindamycin was added for 2 patients: 6 patients given ceftazidime (soft tissue infection, n = 3; nosocomial aspiration bronchopneumonia, n = 3) and 7 given pefloxacin (nosocomial aspiration bronchopneumonia, n = 3; soft tissue infection, n = 3; intra-abdominal abscess, n = 1). No other kinds of antimicrobial agents were given simultaneously with the studied drugs.
Therapeutic efficacy was evaluated by clinical and bacteriological criteria during treatment and after the completion of therapy up to a minimum of 6 weeks; in cases of osteomyelitis, malignant external otitis, and prostatitis, a minimum of 12 months was required.
Clinical cure was defined as defervescence and complete resolution of the signs and symptoms resulting from the principal infection without relapse during at least a 6-week follow-up period; improvement was defined as the amelioration of signs and symptoms without complete cure; relapse was defined as the reappearance of the initial signs and symptoms during the follow-up period; and failure was defined as the lack of any favorable response or deterioration of clinical conditions during therapy.
Bacteriologically, a patient was considered cured if the original causative microorganism was eradicated during therapy without any relapse during the follow-up period; relapse was defined as the reappearance of the original causative organism during the follow-up period after the completion of treatment; persistence was indicated if the originally isolated pathogen persisted in cultures during treatment; and superinfection was defined as the development during treatment of infection at the original site caused by a pathogen (other than a virus) which was not recognized as the original causative organism.
Evaluation of the safety of ceftazidime and pefloxacin in all patients included tests of liver and kidney function and blood counts performed before, during, and after therapy.
Statistic evaluation was performed by using the chi-square test (5) . RESULTS Aerobic culture results are shown in isolates, and the pefloxacin group consisted of 58 isolates from 53 infections, of which 5 were polymicrobial. Haemophilus influenzae was isolated in one and six instances, respectively, in the ceftazidime and pefloxacin groups. Acinetobacter anitratus was isolated initially from four patients in the pefloxacin group, and two non-P. aeruginosa Pseudomonas strains (P. maltophilia and P. fluorescens) were isolated in the ceftazidime group only. The remaining strains were fairly equally divided between the two groups. Five patients, two in the ceftazidime group and three in the pefloxacin group, had positive blood cultures: three with Escherichia coli (acute pyelonephritis, n = 2; acute cholangitis, n = 1), one with Salmonella enteritidis, and one with Flavobacterium spp. (acute endocarditis).
As a prerequisite to entering the trial, the isolated strains had to be found to be susceptible to both ceftazidime and pefloxacin. In the disk diffusion susceptibility tests, an inhibitory zone of >20 mm was determined for all aerobic isolates. MICs of ceftazidime and pefloxacin ranged, respectively, as follows: members of the family Enterobacteriaceae, 0.12 to 0.5 and <0.03 to 0.25 ,ug/ml; Pseudomonas spp., 0.5 to 8 and 0.12 to 4 ,ug/ml; A. anitratus, 4 to 16 and 0.5 to 4 ,ug/ml; H. influenzae, 0.06 to 0.25 and <0.03 to 0.25 ,ug/ml; and Flavobacterium sp., 0.25 and 4 ,ug/ml.
From anaerobic cultures of pus specimens obtained from all patients with soft tissue infections and intra-abdominal abscesses, Bacteroidesfragilis (n = 6) and Peptostreptococcus spp. (n = 1) resistant to both ceftazidime and pefloxacin were isolated.
More than 30% of isolated P. aeruginosa strains were resistant to carbenicillin and to gentamicin-tobramycin-netilmicin while 14% were resistant to all the above-mentioned antibiotics. Almost 50% of the isolated members of the Enterobacteriaceae were found to be resistant to ampicillin and narrow-spectrum cephalosporins, and 50% of A. anitratus strains were resistant to all tested aminoglycosides. Tables 2, 3 , and 4 show the overall bacteriological and clinical results at a 6-week-posttreatment follow-up. Clinically, in the ceftazidime group 78% of the studied patients were cured, 14% improved, and 8% failed to respond, whereas in the pefloxacin group 71.7% were cured, 18.9% improved, and 9.4% failed to respond to therapy (P = not significant). Bacteriologically, in the ceftazidime group the pathogen was eradicated in 80% of the patients and persisted in 20%; in the pefloxacin group the pathogen was eradicated in 79.3% and persisted in 15.1%, while in 5.6% of the patients a bacteriological result could not be obtained (P = not significant).
For all patients with positive blood cultures, therapy was successful both clinically and bacteriologically. With respect to follow-up results obtained after 6 weeks until the 6-month-posttreatment discontinuation, of 39 patients considered to be cured at 6 weeks post-ceftazidime discontinuation, 2 had relapsed (1 patient with acute pyelonephritis and 1 patient with chronic osteomyelitis); whereas of 38 in the pefloxacin group, 3 had relapsed (2 patients with deep soft tissue infection and 1 patient with chronic osteomyelitis) and 2 were lost to follow-up. In all relapses, P. aeruginosa was the causative agent.
The correlation of the isolated species with the reported bacteriological result did not reveal any significant difference between the two groups ( Table 2) . Even among P. aerugi- In three patients superinfections, as defined by the development during therapy of a new infection at the originally infected site, were reported: (i) in the ceftazidime group one case of acute pyelonephritis caused by Enterococcus faecalis in a patient suffering from P. aeruginosa upper UTI with underlying obstructive uropathy and (ii) in the pefloxacin group two cases of bronchopneumonia caused by P. aeruginosa and Pseudomonas diminuta (both susceptible to pefloxacin) in patients with underlying bronchiectasis treated with pefloxacin for Enterobacter cloacae and P. aeruginosa bronchopneumonia, respectively. Details on patients in whom resistance to the administered antimicrobial agent developed during therapy are given in Table 5 . Development of resistance was observed four times (8%) in the ceftazidime group and five times (9.1%) in the pefloxacin group (P = not significant).
Adverse reactions were reported in 15 instances with pefloxacin but in only 3 instances with ceftazidime (P < 0.01). They were deemed serious enough to terminate therapy with two patients in the pefloxacin group because of photosensitivity rash, while in the remaining patients they were self-limited either during therapy or immediately posttherapy completion. The side effects included photosensitivity after exposure to intense sunlight (seven patients on pefloxacin); diffuse maculopapular rash (two patients on ceftazidime and one on pefloxacin); nausea, vomiting, and gastrodynia (two patients on pefloxacin); dizziness (two patients on pefloxacin); diarrhea with negative cultures for Clostridium difficile (one patient on pefloxacin); leg edema (one patient on pefloxacin); abnormal creatinine elevation (one patient on ceftazidime); and abnormal transaminase elevation (one patient on pefloxacin). Gastrointestinal side effects in patients on pefloxacin occurred only when the drug was given orally.
DISCUSSION
Despite their early promise of efficacy, broad-spectrum cephalosporins have not entirely fulfilled expectations in the therapy of gram-negative-bacterial infections. Part of the explanation lies in the following: (i) the emergence during therapy of derepressed mutants of P. aeruginosa and Proteus indole-positive and Providencia, Serratia, and Citrobacter spp. (21, 28) ; (ii) the recognition of new classes of plasmid-mediated P-lactamases with the ability to hydrolyze the newer cephalosporins (1, 18); (iii) superinfections with E. faecalis; (iv) undesirable adverse reactions, such as bleeding disorders and C. difficile enterocolitis; and (v) disturbance of gut colonization resistance. The newer quinolones are characterized by a broad spectrum of activity, rapid bactericidal effect, insusceptibility to plasmid-mediated resistance mechanisms without cross resistance with any other class of antibiotics, and lack of influence on colonization resistance and are available in both oral and parenteral formulas. These agents have been recognized as safe antimicrobial agents, and their development is considered a great step in the field of antimicrobial chemotherapy (3, (24) (25) (26) . However, the newer quinolones have been incriminated in superinfections and breakthrough bacteremias with streptococci mainly in immunocompromised hosts (31) , while development of resistance during therapy, connected in particular with P. aeruginosa and associated with clinical failures in almost 50% of the failed patients, has reached a rate of 30% (11) . True-quinolone-safety profiles should be a matter of postmarketing monitoring, as was done with the newer betalactams.
Pefloxacin efficacy in immunocompetent hosts has been established in noncomparative clinical trials with a variety of gram-negative-bacterial infections, as well as with staphylococcal bone infections (2, 7, 19 In the present study, in which patients suffering from moderate to serious gram-negative-bacterial infections (and underlying aggravating factors in 83.5% of them) were included, the overall favorable clinical efficacy rates (cure plus improvement) did not differ in the two treatment groups (92 versus 90.6%) and were accompanied by similar favorable bacteriological eradication rates (80 versus 79.3%). Notably, UTIs in this study concerned acute pyelonephritis, an infectious disease often connected with sepsis. Among patients suffering from chronic osteomyelitis, a discrepancy related to the duration of therapy was unavoidable because pefloxacin, which is also available as an oral preparation, was given for 4 to 6 months while ceftazidime was given for only 6 to 8 weeks. Despite the fact that therapeutic results were equally successful and therefore in favor of ceftazidime, a large number of patients divided into several subgroups is necessary for establishing the required duration of treatment.
In almost 50% of the infections in this study, P. aeruginosa was implicated as a nosocomial pathogen. Even against this microorganism, pefloxacin and ceftazidime, a cephalosporin characterized by its major antipseudomonal activity (4, 6, 10) , did not reveal any significant difference in efficacies.
Emergence of resistance to the administered antimicrobial agent during therapy involved only P. aeruginosa. The incidences of resistance did not differ in the groups and were observed mostly in patients with chronic ear infections and/or underlying predisposing conditions. Our previous experience with ciprofloxacin, the most potent newer quinolone in vitro against P. aeruginosa, showed a similar rate of resistant P. aeruginosa strains emerging during therapy (12) . It is probable that the administration of a higher dose or combination with another antipseudomonal antibiotic could have prevented that event.
With regard to adverse reactions, patients treated with pefloxacin showed a quite high incidence of skin photosensitivity (13.2%). This is the highest percentage ever reported; in cumulative results from several quinolone studies a much lower incidence of 0.93%, almost exclusively encountered in pefloxacin-treated patients, was reported (15) . Therefore, the possibility of photosensitivity reactions should be a matter of concern for ambulatory patients in countries with intense sunshine.
With the increased use of the broad-spectrum cephalosporins and aminoglycosides, resistance to them has already emerged (14) . In addition, aminoglycoside toxicity restricts the broad application of these agents. Despite the fact that a larger number of patients with more serious infections is required for drawing certain conclusions, based on the results of this study it is evident that pefloxacin was almost as effective as ceftazidime. However, pefloxacin, along with the other fluoroquinolones, should not be prescribed as a first-line antimicrobial agent, to avoid the emergence of resistant mutants. These agents should rather be restricted to cases in which activity against multiresistant enterobacteriaceal species and P. aeruginosa in hospitalized patients is necessary or whenever prolonged therapy with oral agents possessing advantageous pharmacokinetics is required.
